Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
A continuous 100 mg dosing schedule of palbociclib was tolerable but not associated with improved efficacy signals versus the standard intermittent 125 mg (days 1-21 of a 28-day cycle) schedule. Mutations detected in liquid biopsies and changes in cfDNA dynamics were linked to poor outcomes and may identify patients with treatment-resistant cancer.
Authors
- Philip Awadalla (ORCID: https://orcid.org/0000-0001-9946-6393)
- Christine Desbiens (ORCID: https://orcid.org/0000-0002-8922-6406)
- Shuo Shuo Liu (ORCID: https://orcid.org/0000-0001-8396-4515)
- Angela DeLuca (ORCID: https://orcid.org/0009-0005-9971-9529)
- Mark Clemons (ORCID: https://orcid.org/0000-0001-9392-8219)
- Bingshu E. Chen
- Anil A. Joy (ORCID: https://orcid.org/0000-0003-4201-8930)
- Melanie Spears (ORCID: https://orcid.org/0000-0002-1535-4675)
- Julie Lemieux (ORCID: https://orcid.org/0000-0002-6168-320X)
- Louis Gasparini (ORCID: https://orcid.org/0000-0002-5418-6176)
- Alexander Fortuna (ORCID: https://orcid.org/0000-0002-5587-2151)
- Jane Bayani (ORCID: https://orcid.org/0000-0002-1699-5888)
- Wendy R. Parulekar (ORCID: https://orcid.org/0000-0002-6007-7494)
- Karen A. Gelmon (ORCID: https://orcid.org/0000-0003-4111-2757)
- Trevor J. Pugh (ORCID: https://orcid.org/0000-0002-8073-5888)
- Ilinca M. Lungu (ORCID: https://orcid.org/0000-0002-9996-5771)
- David Soave (ORCID: https://orcid.org/0000-0002-1325-7417)
- Nicholas Cheng (ORCID: https://orcid.org/0009-0007-9174-1099)
- John M.S. Bartlett (ORCID: https://orcid.org/0000-0002-0347-3888)
- Sara Taylor (ORCID: https://orcid.org/0000-0002-4437-1378)
- Mihaela Mates (ORCID: https://orcid.org/0009-0009-0982-3592)
Institutions
- Interior Health (CA)
- Ontario Institute for Cancer Research (CA)
- BC Cancer Agency (CA)
- University Health Network (CA)
- University of Waterloo (CA)
- University of Alberta (CA)
- Toronto Public Health (CA)
- University of Toronto (CA)
- Queen's University (CA)
- Western General Hospital (GB)
- Ottawa Hospital (CA)
- Edinburgh Cancer Research (GB)
- Princess Margaret Cancer Centre (CA)
- University of Oxford (GB)
- Centre hospitalier universitaire de Québec (CA)
- Research Canada (CA)
- Ludwig Cancer Research (GB)
- Public Health Ontario (CA)
- Centre hospitalier de l'Université Laval (CA)
- Cancer Care South East (CA)
- Dovetail Genomics (United States) (US)
- Kingston Health Sciences Centre (CA)
- Cancer Research UK Oxford Centre (GB)
- Université Laval (CA)
- Ottawa Hospital Research Institute (CA)
- Wilfrid Laurier University (CA)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0346
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Memorial Sloan-Kettering Cancer Center
- Government of Ontario